Libo Chen
Impact in
- Hepatology top 5%
- Hepatocellular Carcinoma Treatment and Prognosis
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers
Papers in
-
- MicroRNA in disease regulation 5
- Oncology 7
- Pancreatic and Hepatic Oncology Research 3
- Cancer Cells and Metastasis 2
- Co-authors
- Guobin Wang (5 shared papers)Ke Wu (2 shared papers)Xiaoming Lu (1 shared paper)Hang Li (1 shared paper)Qichang Zheng (1 shared paper)Jun Liu (1 shared paper)Liang Shi (1 shared paper)Kaixiong Tao (1 shared paper)
- Journals
- Journal of Clinical Investigation (2 papers)Toxics (2 papers)BMC Cancer (1 paper)Journal of Hazardous Materials (1 paper)Annals of Nuclear Medicine (1 paper)
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Libo Chen
47 papers receiving 1.5k citations
Peers
Comparison fields: 5 of 84
- Hepatology 144
- Oncology 309
- Genetics 114
- Cancer Research 165
- Immunology 169
Countries citing papers authored by Libo Chen
This map shows the geographic impact of Libo Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Libo Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Libo Chen more than expected).
Fields of papers citing papers by Libo Chen
This network shows the impact of papers produced by Libo Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Libo Chen. The network helps show where Libo Chen may publish in the future.
Co-authors
The 25 scholars most cited alongside Libo Chen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 50 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2012 | 431 | |
| 2 | 2004 | 240 | |
| 3 | 2011 | 119 | |
| 4 | 2016 | 86 | |
| 5 | 2010 | 85 | |
| 6 | 2021 | 51 | |
| 7 | Radioiodine therapy of hepatoma using targeted transfer of the human sodium/iodide symporter gene. | 2006 | 44 |
| 8 | 2011 | 35 | |
| 9 | 2008 | 34 | |
| 10 | 2018 | 32 | |
| 11 | 2021 | 26 | |
| 12 | 2012 | 23 | |
| 13 | 2021 | 23 | |
| 14 | 2001 | 20 | |
| 15 | 2006 | 19 | |
| 16 | 2020 | 15 | |
| 17 | 2009 | 14 | |
| 18 | 2010 | 14 | |
| 19 | 2017 | 14 | |
| 20 | 2017 | 14 |
About Libo Chen
Libo Chen is a scholar working on Cancer Research, Oncology, Hepatology, Immunology and Allergy and Radiology, Nuclear Medicine and Imaging, having authored 50 papers that have together received 1.5k indexed citations. Recurring topics across this work include MicroRNA in disease regulation (5 papers), Radiopharmaceutical Chemistry and Applications (3 papers), Sarcoma Diagnosis and Treatment (3 papers), Pancreatic and Hepatic Oncology Research (3 papers), Effects and risks of endocrine disrupting chemicals (3 papers), Cell Adhesion Molecules Research (3 papers), Hepatitis B Virus Studies (2 papers) and Cancer Cells and Metastasis (2 papers). The work is most often cited by research in Hepatology (144 citations), Oncology (309 citations), Genetics (114 citations), Cancer Research (165 citations) and Immunology (169 citations). Libo Chen has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Guobin Wang, Ke Wu, Xiaoming Lu, Hang Li, Qichang Zheng, Jun Liu, Liang Shi, Kaixiong Tao, Weiping Zou and Lian Yang. Their work appears in journals such as Journal of Clinical Investigation, Toxics, BMC Cancer, Journal of Hazardous Materials and Annals of Nuclear Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.